T1	p 77 106	anemic patients with cancer .
T2	p 222 262	patients with cancer-associated anemia .
T3	p 284 301	Eligible patients
T4	p 577 654	hundred sixty-five patients were enrolled . One hundred eighty-three patients
T5	i 59 73	erythropoietin
T6	i 138 150	epoetin alfa
T7	i 205 217	epoetin alfa
T8	i 372 391	epoetin alfa 40,000
T9	i 437 467	standard weekly epoetin alfa (
T10	i 494 508	epoetin alfa (
T11	i 1544 1556	epoetin alfa
T12	i 1751 1763	epoetin alfa
T13	o 771 802	patients requiring transfusions
T14	o 1170 1261	mean end-of-study Hb levels . Toxicities , including thromboembolism , and overall survival
T15	o 1314 1344	global quality of life ( QOL )
T16	o 1426 1448	global QOL improvement